Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Pulls Celebrex's FAP Indication Quickly After Slow Trial Results

This article was originally published in The Pink Sheet Daily

Executive Summary

The European Medicines Agency issues a formal review, even though the claim had been withdrawn, in order to discourage off-label use.
Advertisement

Related Content

COX-2 Inhibitors No Longer The Pits: Tragara's Apricoxib Shows Potential In Phase II APRICOT-L Lung Cancer Trial
COX-2 Inhibitors No Longer The Pits: Tragara's Apricoxib Shows Potential In Phase II APRICOT-L Lung Cancer Trial
Roche Succeeds In Changing EMA Ruling On Avastin
February Supplemental Approvals
February Supplemental Approvals
Pfizer Pulls Mylotarg For Safety 10 Years After Accelerated Approval
Celebrex Gets Committee Nod For Juvenile Arthritis, But Safety Registry Urged
Confirmatory Trial Early Planning Is Essential To Address Potential Problems
COX-2 Inhibitors Contraindicated For Heart Disease Patients In Europe

Topics

Advertisement
UsernamePublicRestriction

Register

PS072301

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel